Trial Profile
An Open-Label, Multi-center, Phase 2 Study of Switch Maintenance With TAS-102 Plus Bevacizumab Following Oxaliplatin or Irinotecan-Based Fluoropyrimidine-Containing Induction Chemotherapy in Patients With Metastatic Colorectal Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Aug 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms ALEXANDRIA
- 11 Jul 2018 Status changed to discontinued as principal investigator left the institution
- 15 Nov 2017 Status changed from active, no longer recruiting to completed.
- 30 Aug 2017 Status changed from recruiting to active, no longer recruiting.